Merck Sues Over Medicare Drug-Price Negotiation Law

The company is heavily reliant on a cancer drug that could be targeted by a program intended to lower drug prices.

Rebecca Robbins
Author: Rebecca Robbins

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.